WHO experts “strongly recommend” not using Xevudy, based on the sotrovimab molecule, and Ronapreve, based on the casirivimab-imdevimab combination, in the latest version of their anticovid treatment guide, published early Friday in the British Medical Journal.
Xevudy, developed by the GSK and Vir laboratories, and Ronapreve, developed by Regeneron, are two treatments with synthetic antibodies against covid-19.
Until now, the WHO prudently recommended its use in patients affected by a mild form of the disease, and not in cases of risk of its progression to a more severe form, due to age, weight or other factors.
However, the arrival of the omicron variant at the end of 2021 called into question the interest of these treatments and WHO experts, based on several in vitro studies, now estimate that they are probably ineffective against circulating variants.
The experts also updated the recommendations on other treatments, especially Remdesivir from the Gilead laboratory.
This treatment, of which the WHO did not recommend the use until now except in the case of a mild form of covid, can, according to new studies, be contemplated in some severe cases, according to experts.
However, in the most severe cases, called “critical”, studies do not show a benefit from Remdesivir. Experts do not advise use in those cases.
The entrance The WHO recommends not to use two treatments with antibodies was first published in diary TODAY.
